Vaxart
Update in progressVXRT (OTC Markets OTCQX)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant protein vaccines using its vector-adjuvant-antigen platform. Its pipeline includes a bivalent norovirus oral tablet in Phase 2 for GI.1 and GII.4; a COVID-19 vaccine in Phase 2b for SARS-CoV-1, SARS-CoV-2, and MERS; a seasonal influenza vaccine in Phase 2 for H1N1; and a preclinical HPV therapeutic vaccine targeting HPV-16/18. It licenses Vapendavir from Altesa. HQ: South San Francisco.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.07
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketOTC Markets OTCQX (OQX)
- LocationUnited States
- CEOMr. Steven Lo
- Employees65
- Websitevaxart.com
Identifiers
- ISINUS92243A2006
- FIGIBBG000DR0RZ7
- CUSIP053761102
- CIK0000072444